80 results
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
establish adequate coverage, reimbursement levels, and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product … that would potentially support registration and reimbursement in SCT.
An investigator-sponsored open-label Phase1b/2 study in Bronchiolitis Obliterans
10-K
2023 FY
EX-10.30
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
, pricing and reimbursement issues, and other
Page 3 of 48
EXECUTION VERSION
CONFIDENTIAL
relevant factors commonly considered in similar … Approval (including for these purposes any pricing and reimbursement approval that may be required) by the applicable Regulatory Authority
10-K
2023 FY
EX-4.2
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
and charges of, and reimbursement of the applicable expenses incurred by, the depositary.
Books of Depositary
The depositary will maintain ADS holder records
10-K
2023 FY
EX-97.1
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
reimbursement of cash Erroneously Awarded Compensation previously paid to the Covered Executive; (b) seeking recovery of any gain realized
8-K
EX-99.1
MREO
Mereo Biopharma Group Plc
27 Mar 24
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
4:08pm
to invest in pre-launch activities and other studies to generate further evidence that will inform coverage, pricing and reimbursement decisions in the EU … with setrusumab.
The Company continues to build a compelling evidence base to support productive pricing and reimbursement discussions in the EU
6-K
EX-99.2
9q346zf p4s2
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.1
8ah5y9l4pu0b1 r8se
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.2
c179w6y4e
2 Nov 22
Current report (foreign)
4:17pm
6-K
EX-99.1
twxmh
31 Aug 22
Letter Reiterates Mereo’s Updated Strategic Plan to Maximize Value for All Shareholders and Corrects Rubric’s Assumptions
7:57am